Oral Semaglutide: Rybelsus, Ozempic Tablets and the Wegovy Pill, Explained

"Oral semaglutide" sounds like one product. It is legally three — Rybelsus, Ozempic tablets, and the Wegovy pill — sold at three different milligram strengths, for two different FDA-approved purposes, by the same manufacturer. Confusing Rybelsus with an oral Wegovy is the single most common mix-up in this category, and the prescribing information settles it precisely.

Rybelsus and Ozempic tablets treat diabetes, not obesity

Per the combined FDA prescribing information for Rybelsus and Ozempic tablets, both are indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" and to reduce cardiovascular risk in adults with type 2 diabetes at high risk — full stop. Neither carries a weight-management indication¹. That has not stopped widespread off-label use for weight loss, but if you've heard someone call Rybelsus "the pill version of Wegovy," that's not what its own label says it's for. The label goes further with a detail almost nobody expects: Rybelsus and Ozempic tablets "are not substitutable on a mg-to-mg basis"¹ — despite being the identical molecule for the identical indication, Rybelsus titrates 3 mg → 7 mg → 14 mg while Ozempic tablets titrate 1.5 mg → 4 mg → 9 mg, two different dosing ladders for the same drug under two different brand names.

The Wegovy pill is a genuinely different product

Wegovy tablets are a separate, newer formulation with the indication Rybelsus lacks: weight reduction and cardiovascular risk reduction in adults with obesity or overweight, on the same combined label as Wegovy's injection². It follows Wegovy injection's own brand split — Ozempic is the diabetes brand of injectable semaglutide, Wegovy the weight-management brand of the same molecule — mapped onto the oral form. The Wegovy tablet's titration starts at 1.5 mg once daily, climbs in a step-up schedule, and reaches a 25 mg once-daily maintenance dose² — nearly double Rybelsus's 14 mg ceiling, because the two tablets are calibrated for different jobs, not different potencies of the same treatment.

All three use the same absorption trick — and the same strict rules

Every oral semaglutide tablet, including the Wegovy pill, is built around SNAC (salcaprozate sodium), an absorption enhancer that lets a fraction of the peptide survive the stomach. That mechanism is why all three share the same non-negotiable instructions: take the tablet on an empty stomach with no more than 4 ounces of plain water, swallow it whole without splitting or crushing, and wait at least 30 minutes before eating, drinking anything else, or taking another oral medication¹³. Skip that window and less of the dose reaches circulation — a real pharmacokinetic constraint, not a suggestion. It is also why the injectable and oral versions are not simply interchangeable: switching between WEGOVY injection and WEGOVY tablets requires a specific protocol², not a same-day swap.

What the trial evidence actually shows about oral dosing

The Wegovy tablet's 25 mg approved ceiling is not the highest dose that has been studied. In OASIS 1, a phase 3 trial of a 50 mg once-daily oral semaglutide dose — double today's approved maximum — patients lost significantly more weight than placebo over 68 weeks⁴, evidence that oral semaglutide's efficacy ceiling has room above the currently approved dose, similar in spirit to how Wegovy injection's own label permits up to 7.2 mg even though 2.4 mg is the commonly cited number. Oral bioavailability from SNAC-based absorption is inherently lower and more variable than a subcutaneous injection³, which is the pharmacological reason oral doses run so much higher in milligrams than their injectable counterparts for a comparable effect.

What this costs, from providers who actually disclose it

Brand Rybelsus, Ozempic tablets, and the Wegovy pill are dispensed through the same cash-pay and insurance channels as their injectable siblings — see what a GLP-1 costs without insurance for the manufacturer self-pay routes. On the compounded side, several providers we track disclose real oral-tablet pricing rather than injection-only menus: Somi Health offers a compounded oral semaglutide tablet alongside its $135/mo injectable, and Mevo Health lists compounded oral tablets at $199/mo across all doses. Compounded oral tablets are not the FDA-reviewed SNAC formulation studied in the trials above, and — per several providers' own published cons — carry weaker efficacy data than injectable semaglutide, so verify the pharmacy the same way you would for any compounded product before choosing pills over the needle on price alone. A structurally different oral option worth knowing about, if needles are the deciding factor: LillyDirect's Foundayo, a non-peptide oral GLP-1 that does not rely on SNAC or an empty-stomach window at all.

The takeaway

If your prescriber writes "Rybelsus" or "Ozempic tablets," you are being treated for glycemic control at doses topping out at 14 mg or 9 mg; if it says "Wegovy tablets," you are on the weight-management product dosed up to 25 mg — and the two are not interchangeable pill-for-pill any more than Ozempic and Wegovy injections are. Confirm which product and which indication your plan is actually built around, and price the real route — brand or verified compounded — against the full molecule comparison before assuming "oral" automatically means cheaper or weaker. The labels and trials behind this are indexed in our research library. Not medical advice — see our medical disclaimer and confirm your own prescription with your clinician.